Frank Hsu

Dr. Hsu joined Apexigen as Chief Medical Officer in August of 2021. He is a medical oncologist with more than 30 years of clinical cancer research and development experience in the biotech industry and academics. Most recently, he served as Chief Medical Officer of Oncternal Therapeutics where he oversaw the development of both antibody and small molecule therapeutics. Earlier in his career, he served as Vice President and Head of Oncology at Immune Design Corporation, where he was responsible for the development of several immuno-oncology programs, and as Chief Medical Officer at Zyngenia, Inc., where he was responsible for the development of its multivalent antibody/protein therapeutics. Dr. Hsu started his biotech industry career as a Senior Medical Director at Genzyme Corporation, and over a 10 year period led several multifunctional teams and oversaw the clinical development of investigational and approved agents, including Mozobil®, Campath®, fresolimumab, and other immuno-oncology agents.